Two doses of Johnson & Johnson’s vaccine are 94% effective in fighting symptomatic infections caused by COVID-19, according to a new study. The research was carried out by the pharmacist itself, based on data collected in the United States in phase two of the study. From what the report says, the efficacy of this vaccine is now comparable to the Moderna and Pfizer doses.
Two doses of Johnson & Johnson’s vaccine are 94% effective in fighting symptomatic infections caused by COVID-19, according to a new study. The research was carried out by the pharmacist itself, based on data collected in the United States in phase two of the study. From what the report says, the efficacy of this vaccine is now comparable to the Moderna and Pfizer doses.